País: Irlanda
Idioma: inglés
Fuente: HPRA (Health Products Regulatory Authority)
DEXAMETHASONE
Alcon Laboratories (UK) Ltd
S01BA01
DEXAMETHASONE
0.1 %w/v
Eye Drops Suspension
Product subject to prescription which may be renewed (B)
Corticosteroids, plain
Authorised
1984-01-05
REPORT FOR: 641005.PDF(1-225989) PAGE: 1 REPORT FOR: 641005.PDF(1-225989) PAGE: 2 Leer el documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Maxidex 0.1% w/v Eye Drops, Suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Dexamethasone 0.1% w/v. Excipients: Contains 0.01% w/v Benzalkonium Chloride For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Eye drops, suspension Whitish suspension, free from flocculates. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Indicated for the treatment of allergic and inflammatory conditions of the eye. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults, adolescents and children (2 years of age and above) One drop instilled into the conjunctival sac every 30-60 minutes for 3-4 days or until a satisfactory response occurs. Method of Administration For ocular use only. Shake the bottle well before use After cap is removed, if tamper evident snap collar is loose, remove before using product Do not let the tip of the dropper touch the eye Nasolacrimal occlusion or gently closing the eyelid for 2 minutes after administration is recommended. This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic adverse reactions. Paediatric patients The safety of this product has not been established in children below 2 years of age Elderly population No overall differences in safety or effectiveness have been observed between elderly and younger patients. Hepatic and renal impairment The safety and efficacy of MAXIDEX in patients with hepatic or renal impairment have not been established. HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 11/10/2016_ _CRN 2176029_ _page number: 1_ 4.3 CONTRAINDICATIONS Ocular viral infections such as vaccinia, varic Leer el documento completo